Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top
CSL 2023 Half Year Earnings Results: Are you satisfied?
CSL delivered a net profit after tax of $1.6 billion for H1 2023, steady at constant currency(CC). This included one-off costs associated wi Show More
CSL delivered a net profit after tax of $1.6 billion for H1 2023, steady at constant currency(CC). This included one-off costs associated with the acquisition of Vifor Pharma. The underlying profit was $1.82 billion, up 10% YoY and revenue was up 25% YoY at CC.

Business Highlights:
●Successful closure of Vifor acquisition: 15% revenue growth; Integration underway and cost synergies on track.
● Statutory net profit after tax (NPAT) earnings per share was $3.77.
●HEMGENIX® was approved by FDA, the first gene therapy for haemophilia B.
●Licence agreement for late-stage self-amplifying mRNA vaccine technology.
● FY23 NPATA is estimated to be in the range of $2.7 billion to $2.8 billion approximately at CC
Q: 1) Is now a good time to own CSL Limited stocks?
   2) What's your opinion or analysis of the company?
Views
4395
Posts
4
Join topic
Latest
Hot